Pomerantz LLP is investigating Larimar Therapeutics and its executives for potential securities fraud following disclosures about severe allergic reactions in patients during clinical trials of their drug nomlabofusp. The drug, aimed at treating Friedreich’s Ataxia, showed safety issues with multiple cases of anaphylaxis, causing Larimar's stock to drop significantly twice in 2025 and 2026. The investigation seeks to determine if the company misled investors about the drug's safety. This legal action could impact investor confidence and the company's future regulatory approvals.
Sanoma Corporation will publish its Half-Year Report for the period January to June 2026 on July 29, 2026. The report and related materials will be available on their website, followed by an analyst and investor conference held in Helsinki and access...
Sanoma Oyj will publish its half-year financial report for January to June 2026 on July 29, 2026, at around 8:30 AM. The report and related materials will be available immediately on Sanoma's investor website. An English-language briefing for analyst...
AMSilk and Ajinomoto Foods Europe (AFE) have expanded their partnership with a long-term manufacturing and supply agreement to scale industrial production of silk proteins. AFE will establish a dedicated production line at its Nesle, France site usin...
The global ambient light sensor market, valued at $3.81 billion in 2025, is projected to reach $9.54 billion by 2035 with a CAGR of 9.63%. Growth is fueled by rising demand for smart devices like smartphones and wearables, energy-efficient displays, ...
Payhawk, an AI-native spend management platform, has surpassed $100 million in annual recurring revenue (ARR), achieving 159% year-over-year growth in new business and 95% growth in payment volumes. The company rebuilt its products and operations aro...
